ly-2090314
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT01287520)
Timeline
Indications
Mechanism of action
- Glycogen synthase kinase-3 alphaINHIBITOR
GSK3A inhibitor
- Glycogen synthase kinase-3 betaINHIBITOR
GSK3B inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2- Mol. weight
- 512.55 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL362558 ↗
Also known as
- 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1h-pyrrole-2,5-dione
- ly2090314
- ly2090314
- ly2090314
- ly-2090314
- ly-2090314
- ly-2090314
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01632306 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | Eli Lilly, Mayo Clinic |
| NCT01214603 | Phase 2 | Nov 1, 2010 | Eli Lilly |
| NCT01287520 | Phase 1 | Nov 1, 2007 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 2 | 2007 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1